MiMedx Group
NasdaqCM:MDXG Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
WA
Consensus Narrative from 5 Analysts
CMS Policy Changes And HELIOGEN Launch Will Impact Future Prospects Amid Challenges
Key Takeaways MiMedx expects policy corrections and product expansion to drive revenue and profit growth, aided by improved Medicare reimbursements and new product launches. International expansion and R&D investments support global sales growth, while customer loyalty initiatives enhance long-term profitability and margins.
View narrativeUS$13.40
FV
40.4% undervalued intrinsic discount10.36%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
25 days ago author updated this narrative